biostudies-literatureUnknown31(9)Rodriguez-Moreno JF<h4>Purpose</h4>Neoadjuvant treatment of bladder cancer is evolving, with immunotherapy demonstrating promising activity. PARP inhibition combined with immune activation has been proposed as a synergistic strategy. We conducted a comprehensive molecular characterization of tumors treated with this combination in the neoadjuvant setting to provide crucial results for rational development.<h4>Patients and methods</h4>A phase II clinical trial was designed to evaluate the combination of anti-PDL1 inhibitor durvalumab and PARP inhibitor olaparib, focusing on biomarker dynamics in both pre- and post-treatment settings. A total of 29 patients were enrolled. Genomic and transcriptomic profiling, as well as analyses of immune cell populations, was conducted at baseline and at the time of cystectomClinical cancer research : an official journal of the American Association for Cancer Research1644-1656https://www.ebi.ac.uk/biostudies/studies/S-EPMC12010967biostudies-literatureTreatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.PMC12010967Vazquez SBeltran LVirizuela JAGrana-Castro ORodriguez-Antona Cde Velasco GBerraondo PGajate PMadurga RRodriguez-Moreno JFCollado RGarcia-Donas JFont AAlvarez-Fernandez CSevillano-Fernandez ERuiz-Llorente SFernandez RLainez NfalseTreatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.<h4>Purpose</h4>Neoadjuvant treatment of bladder cancer is evolving, with immunotherapy demonstrating promising activity. PARP inhibition combined with immune activation has been proposed as a synergistic strategy. We conducted a comprehensive molecular characterization of tumors treated with this combination in the neoadjuvant setting to provide crucial results for rational development.<h4>Patients and methods</h4>A phase II clinical trial was designed to evaluate the combination of anti-PDL1 inhibitor durvalumab and PARP inhibitor olaparib, focusing on biomarker dynamics in both pre- and post-treatment settings. A total of 29 patients were enrolled. Genomic and transcriptomic profiling, as well as analyses of immune cell populations, was conducted at baseline and at the time of cystectom2025-01-01T00:00:00Z2025 May2026-06-01T14:52:02.476Z2025-07-06T03:05:34.909ZS-EPMC120109674029840610.1158/1078-0432.CCR-24-2890